Showing 321 - 340 results of 5,822 for search '"Journal for ImmunoTherapy of Cancer"', query time: 1.01s Refine Results
  1. 321
    Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin

    Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin by Jichao Sun, Dinglan Wu, Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Chengchao Xu, Zhijie Li, Jigang Wang

    Published 2024-07-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  2. 322
    863 Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response

    863 Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response by Pia Kvistborg, Anastasia Gangaev

    Published 2020-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  3. 323
    Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

    Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models by Robert W Wilkinson, Hormas Ghadially, Stacy Kentner, Suzanne Isabelle Sitnikova, Sophie Munnings-Tomes, Elena Galvani, Kathy Mulgrew, Chris Rands, Judit España Agustí, Tianhui Zhang, Kristina M Ilieva, Guglielmo Rosignoli, Matthew J Robinson, Tim Slidel, Simon J Dovedi

    Published 2021-06-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  4. 324
    Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

    Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy by Christian Schmidt, Jens Ricke, Marion Subklewe, Veit Bücklein, Michael von Bergwelt-Baildon, Wolfgang G Kunz, Kai Rejeski, Viktoria Blumenberg, Michael Winkelmann, Christina Quell, Maria Ingenerf, Marcus Unterrainer, Franziska J Dekorsy, Peter Bartenstein

    Published 2023-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  5. 325
    1508 Analyzing the genomic, transcriptomic and immune landscapes associated with surface somatostatin receptor 2 (SSTR2) gene expression in nasopharyngeal carcinoma (NPC)

    1508 Analyzing the genomic, transcriptomic and immune landscapes associated with surface somatostatin receptor 2 (SSTR2) gene expression in nasopharyngeal carcinoma (NPC) by James L Gulley, Ari VanderWalde, Emil Lou, Nishant Gandhi, Heloisa Soares, Charalampos S Floudas, Dara Bracken-Clarke, Harris Krause, Minh Phan, Rusha Patel, Phillip Walker

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  6. 326
    GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway

    GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway by Li Liu, Guoqiang Sun, Yongxiang Xia, Xuehao Wang, Hanyuan Liu, Tian Huang, Ziyi Chen, Weiwei Tang, Guangshun Sun, Hengsong Cao, Dawei Rong, Yuliang Wang, Xiaopei Hao, Zhiying Zheng, Junwei Kang

    Published 2023-02-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  7. 327
    677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer

    677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV... by Tc Wu, Francis Worden, Michael K Gibson, Panayiotis Savvides, Ellen Heimann-Nichols, Richard Roden, Yung-Nien Chang

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  8. 328
    CD47 expression is critical for CAR T-cell survival in vivo

    CD47 expression is critical for CAR T-cell survival in vivo by Stephen Gottschalk, Phuong Nguyen, Christopher DeRenzo, Giedre Krenciute, Alex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Peter Vogel, Heather Sheppard

    Published 2023-03-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  9. 329
    Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery

    Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery by Qin Xu, Bing Wang, Yang He, Zening Zheng, Jiaxin Zhang, Jizong Jiang, Wenyuan Zhang, Xiaopeng Mo, Xuejia Kang, Yongzhuo Huang

    Published 2020-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  10. 330
    175 Metastatic triple negative breast cancer has distinct tumor immune landscape

    175 Metastatic triple negative breast cancer has distinct tumor immune landscape by Sarabjot Pabla, Marcia Eisenberg, Shipra Gandhi, Erik Van Roey, Shuang Gao, Shengle Zhang, Shakti Ramkissoon, Mary K Nesline, Maria-Fernanda Senosain, Jeffrey M Conroy, Kyle C Strickland, Heidi Ko, Rebecca A Previs, Taylor J Jensen, Brian Caveney, Eric A Severson, Stephanie B Hastings, Robert Seager

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  11. 331
    Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy

    Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy by Chia-Sing Lu, Ching-Wen Lin, Ya-Hsuan Chang, Hsuan-Yu Chen, Wei-Chia Chung, Wei-Yun Lai, Chao-Chi Ho, Tong-Hong Wang, Chi-Yuan Chen, Chen-Lin Yeh, Sean Wu, Shu-Ping Wang, Pan-Chyr Yang

    Published 2020-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  12. 332
    Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination

    Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination by Sjoerd H van der Burg, Ziena Abdulrahman, Noel de Miranda, Edith M G van Esch, Peggy J de Vos van Steenwijk, Hans W Nijman, Marij J. P. Welters, Mariette I E van Poelgeest

    Published 2020-05-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  13. 333
    372 TAC-T cells persist and remain functional during and after repeated tumor exposure in vitro and in vivo

    372 TAC-T cells persist and remain functional during and after repeated tumor exposure in vitro and in vivo by Swati Shetty, Kyle MacDonald, Sailaja Pirati, Sadhak Sengupta, Heather L MacGregor, Suzanna L Prosser, Stacey X Xu, Aksha Kadri, Ritu R Randhawa, Deepika Bhemarasetty, Christopher W Helsen, Andreas G Bader

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  14. 334
    1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer

    1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer by Jarushka Naidoo, Igor Puzanov, Jair Bar, Niels Reinmuth, Alona Zer, Michal Harel, Adam Dicker, Michal Lotem, Anirban Chatterjee, Mahmoud Abu-Amna, Mor Moskovitz, Adam Hassani, Itamar Sela, Yehonatan Elon, Iris Kamer, Adva Levy-Barda, Abed Agbarya, Ina Koch, David Farrugia, Gillian Price, Tatiana Harkovsky, Rivka Katzenelson, Ben Yelin, Raya Leibowitz

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  15. 335
    451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab

    451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab by Kai Sun, Maen Abdelrahim, Yuqi Zhang, Catherine Wiechmann, Jiaqiong Xu, Ethan Burns, Ryan Kieser, Shivan Shah, Godsfavour Umoru, Abdullah Esmail, Kelly Gee

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  16. 336
    156 Spatial transcriptomic signatures of the fundamentals of immuno-oncology

    156 Spatial transcriptomic signatures of the fundamentals of immuno-oncology by Yan Liang, Patrick Danaher, Joseph Beechem, Sarah Church, Megan Vandenberg, Emily Killingbeck, Sangsoon Woo

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  17. 337
    Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

    Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer by John Wright, Stephanie Lheureux, Ilaria Colombo, Ramy Gadalla, Pamela S Ohashi, Xuan Li, Lisa Wang, Matthew S Block, David G Brooks, Andrea Jewell, Carolyn McCourt, Eugenia Girda, Sarah Temkin, Gini F Fleming, Linda Duska, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Stephanie L Gaillard, Michael McHale, Floor J Backes, Theresa L Werner, Siobhan Kehoe, Rachel Wildman, Shirin Soleimani, Scott Lien, Trevor Pugh

    Published 2022-03-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  18. 338
    BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy

    BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy by Madhuri Koti, Alvaro Morales, Charles H Graham, David Robert Siemens

    Published 2020-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  19. 339
    223 CAR-T cells expressing both IL-7 and CCL19 induce epitope spreading via cross presentation of endogenous tumor antigens

    223 CAR-T cells expressing both IL-7 and CCL19 induce epitope spreading via cross presentation of endogenous tumor antigens by Keishi Adachi, Yukimi Sakoda, Koji Tamada

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  20. 340
    Lung metastases share common immune features regardless of primary tumor origin

    Lung metastases share common immune features regardless of primary tumor origin by Victor Moreno, Julián Pardo, Ramon Salazar, Sandra García-Mulero, M Henar Alonso, Cristina Santos, Xavier Sanjuan, Josep María Piulats, Rebeca Sanz-Pamplona

    Published 2020-05-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article

Search Tools: